Logo image of DHR

DANAHER CORP (DHR) Stock Overview

USA - NYSE:DHR - US2358511028 - Common Stock

222.73 USD
+4.63 (+2.12%)
Last: 10/23/2025, 8:04:00 PM
224.03 USD
+1.3 (+0.58%)
Pre-Market: 10/24/2025, 8:41:19 AM

DHR Key Statistics, Chart & Performance

Key Statistics
Market Cap159.49B
Revenue(TTM)24.27B
Net Income(TTM)3.50B
Shares716.05M
Float638.06M
52 Week High258.23
52 Week Low171
Yearly Dividend1.05
Dividend Yield0.59%
EPS(TTM)7.71
PE28.89
Fwd PE25.9
Earnings (Next)01-27 2026-01-27/amc
IPO1969-12-10
Sector
GICS SectorHealth Care
GICS IndustryLife Sciences Tools & Services
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences


DHR short term performance overview.The bars show the price performance of DHR in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 5 10 15 20

DHR long term performance overview.The bars show the price performance of DHR in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 5 -5 10 -10 15

The current stock price of DHR is 222.73 USD. In the past month the price increased by 22.74%. In the past year, price decreased by -9.23%.

DANAHER CORP / DHR Daily stock chart

DHR Latest News, Press Relases and Analysis

DHR Competitors/Peers

The largest stocks on the US markets in the "Life Sciences Tools & Services" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
TMO THERMO FISHER SCIENTIFIC INC 25.53 215.96B
BRKRP BRUKER CORP - BRKR 6 3/8 09/01/28 147.87 48.23B
A AGILENT TECHNOLOGIES INC 27.06 41.80B
IQV IQVIA HOLDINGS INC 19.17 37.38B
MTD METTLER-TOLEDO INTERNATIONAL 35.15 29.62B
WST WEST PHARMACEUTICAL SERVICES 43.46 22.09B
WAT WATERS CORP 29.08 21.17B
MEDP MEDPACE HOLDINGS INC 41.72 16.76B
ILMN ILLUMINA INC 24.03 15.37B
TEM TEMPUS AI INC N/A 15.12B
ICLR ICON PLC 13.65 14.00B
RVTY REVVITY INC 19.95 11.32B

About DHR

Company Profile

DHR logo image Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. The company is headquartered in Washington, Washington Dc and currently employs 61,000 full-time employees. The firm operates through three segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.

Company Info

DANAHER CORP

2200 Pennsylvania Ave NW Ste 800W

WASHINGTON WASHINGTON DC 20037 US

CEO: Rainer M. Blair

Employees: 62000

DHR Company Website

DHR Investor Relations

Phone: 12028280850

DANAHER CORP / DHR FAQ

What does DHR do?

Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. The company is headquartered in Washington, Washington Dc and currently employs 61,000 full-time employees. The firm operates through three segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.


Can you provide the latest stock price for DANAHER CORP?

The current stock price of DHR is 222.73 USD. The price increased by 2.12% in the last trading session.


Does DHR stock pay dividends?

DANAHER CORP (DHR) has a dividend yield of 0.59%. The yearly dividend amount is currently 1.05.


What is the ChartMill technical and fundamental rating of DHR stock?

DHR has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 5 out of 10.


What is the ex-dividend date for DHR stock?

The next ex-dividend date for DANAHER CORP (DHR) is September 26, 2025.


What is the expected growth for DHR stock?

The Revenue of DANAHER CORP (DHR) is expected to grow by 3.84% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.


Can you provide the upcoming earnings date for DANAHER CORP?

DANAHER CORP (DHR) will report earnings on 2026-01-27, after the market close.


DHR Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to DHR. When comparing the yearly performance of all stocks, DHR is a bad performer in the overall market: 65.71% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

DHR Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to DHR. While DHR belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

DHR Financial Highlights

Over the last trailing twelve months DHR reported a non-GAAP Earnings per Share(EPS) of 7.71. The EPS increased by 3.63% compared to the year before.


Industry RankSector Rank
PM (TTM) 14.43%
ROA 4.38%
ROE 6.86%
Debt/Equity 0.33
Chartmill High Growth Momentum
EPS Q2Q%10.53%
Sales Q2Q%4.4%
EPS 1Y (TTM)3.63%
Revenue 1Y (TTM)2.22%

DHR Forecast & Estimates

29 analysts have analysed DHR and the average price target is 246.54 USD. This implies a price increase of 10.69% is expected in the next year compared to the current price of 222.73.

For the next year, analysts expect an EPS growth of 4.87% and a revenue growth 3.84% for DHR


Analysts
Analysts86.21
Price Target246.54 (10.69%)
EPS Next Y4.87%
Revenue Next Year3.84%

DHR Ownership

Ownership
Inst Owners82.47%
Ins Owners10.82%
Short Float %1.49%
Short Ratio2.33